Though BiPAP is an increasingly common tool used by pediatric critical care physicians and there is promising data suggesting a role for BiPAP in the management of status asthmaticus, more information is needed to more definitively clarify the extent of its benefit, as well as when during an asthma exacerbation and in whom it is the most beneficial. In this study, which is among the first randomized studies of BiPAP use for status asthmaticus in the pediatric population, the investigators hope to better elucidate these issues to help guide clinicians' future management decisions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
Clinical Asthma Scores
Both PRAM and CCMC clinical asthma scores
Time frame: 3 hours after enrollment
Dyspnea Scores
Modified Borg Scale and Wong Baker Faces Scale
Time frame: 0 hours, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, and 36 hours after enrollment
BiPAP Tolerance
Tolerability of BiPAP will be determined by patients keeping the mask on and agreeing to remain on the machine for the intended treatment period.
Time frame: Hospitalization
Length of stay in intensive care unit (ICU)
Time frame: ICU stay -- Expected to be approximately 3 days on average
Length of stay in hospital
Time frame: Hospital length of stay -- Expected to be approximately 5 days on average
Side effects or adverse events
Time frame: Hospitalization
Clinical Asthma Scores
Time frame: 0 hours, 6 hours, 9 hours, 12 hours, 24 hours, and 36 hours after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.